From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.
Moskowitz, David W
From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. [electronic resource] - Diabetes technology & therapeutics 2002 - 519-32 p. digital
Publication Type: Comparative Study; Journal Article
1520-9156
10.1089/152091502760306616 doi
Angiotensin-Converting Enzyme Inhibitors--therapeutic use
Black People
Diabetic Nephropathies--drug therapy
Female
Genomics
Genotype
Humans
Hypertension--drug therapy
Kidney Failure, Chronic--etiology
Male
Missouri
Peptidyl-Dipeptidase A--genetics
Polycystic Kidney, Autosomal Dominant--drug therapy
Polymorphism, Genetic
Pulmonary Disease, Chronic Obstructive--genetics
Sex Characteristics
Treatment Outcome
White People
Black or African American
From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. [electronic resource] - Diabetes technology & therapeutics 2002 - 519-32 p. digital
Publication Type: Comparative Study; Journal Article
1520-9156
10.1089/152091502760306616 doi
Angiotensin-Converting Enzyme Inhibitors--therapeutic use
Black People
Diabetic Nephropathies--drug therapy
Female
Genomics
Genotype
Humans
Hypertension--drug therapy
Kidney Failure, Chronic--etiology
Male
Missouri
Peptidyl-Dipeptidase A--genetics
Polycystic Kidney, Autosomal Dominant--drug therapy
Polymorphism, Genetic
Pulmonary Disease, Chronic Obstructive--genetics
Sex Characteristics
Treatment Outcome
White People
Black or African American